首页> 美国卫生研究院文献>Aging (Albany NY) >Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma
【2h】

Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma

机译:加权基因相关网络分析将微环境相关基因签名作为II / III级胶质瘤的预后候选者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Glioma is the most common malignant tumor in the central nervous system. Evidence shows that clinical efficacy of immunotherapy is closely related to the tumor microenvironment. This study aims to establish a microenvironment-related genes (MRGs) model to predict the prognosis of patients with Grade II/III gliomas. Gene expression profile and clinical data of 459 patients with Grade II/III gliomas were extracted from The Cancer Genome Atlas. Then according to the immune/stromal scores generated by the ESTIMATE algorithm, the patients were scored one by one. Weighted gene co-expression network analysis (WGCNA) was used to construct a gene co-expression network to identify potential biomarkers for predicting the prognosis of patients. When adjusting clinical features including age, histology, grading, IDH status, we found that these features were independently associated with survival. The predicted value of the prognostic model was then verified in 440 samples in CGGA part B dataset and 182 samples in CGGA part C dataset by univariate and multivariate cox analysis. The clinical samples of 10 patients further confirmed our signature. Our findings suggested the eight-MRGs signature identified in this study are valuable prognostic predictors for patients with Grade II/III glioma.
机译:胶质瘤是中枢神经系统中最常见的恶性肿瘤。证据表明,免疫疗法的临床疗效与肿瘤微环境密切相关。本研究旨在建立微环境相关基因(MRGS)模型,以预测II级患者/ III级胶质瘤的预后。从癌症基因组地图集提取459例II / III级肺瘤患者的基因表达谱和临床资料。然后根据估计算法产生的免疫/基质分数,患者逐一缩小。加权基因共表达网络分析(WGCNA)用于构建基因共表达网络以鉴定潜在的生物标志物,以预测患者的预后。在调整包括年龄,组织学,评分,IDH状态的临床特征时,我们发现这些特征与生存有独立相关。然后通过单变量和多变量COX分析验证了在CGGA Part B Dataset中的440个样本中的预测值的预测值和CGGA部分C数据集中的182个样本。 10名患者的临床样本进一步证实了我们的签名。我们的研究结果表明,本研究中鉴定的八MRGS签名是II级/ III级胶质瘤患者的宝贵预测预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号